Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 200Terminated 54Recruiting 47Active not recruiting 20Withdrawn 18Unknown 7Not yet recruiting 4Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 32Neoplasms 28Colorectal Neoplasms 19Prostatic Neoplasms 16Lung Neoplasms 13Leukemia, Myeloid, Acute 12Glioblastoma 12Stomach Neoplasms 10Head and Neck Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Pancreatic Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Melanoma 8Glioma 8Brain Neoplasms 8Rectal Neoplasms 7Carcinoma, Hepatocellular 7Ovarian Neoplasms 6Neoplasm Metastasis 6Hematologic Neoplasms 6Uterine Cervical Neoplasms 5Polycystic Ovary Syndrome 5Myelodysplastic Syndromes 5Multiple Myeloma 5Esophageal Neoplasms 5Carcinoma, Renal Cell 5Triple Negative Breast Neoplasms 4Lymphoma, B-Cell 4Lymphoma 4Depression 4

Interventions

eltrombopag 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × OTHER × Leukemia, Myelomonocytic, Chronic × Clear all
NCT06630221 2026-06-05

Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

Case Comprehensive Cancer Center

Phase 2 Suspended
25 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡